Caprock Group’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.93M | Sell |
45,285
-636
| -1% | -$34.5K | 0.04% | 412 |
|
|
2026
Q1 | $2.88M | Sell |
45,921
-16,612
| -27% | -$1.33M | 0.07% | 246 |
|
|
2025
Q4 | $5.96M | Sell |
62,533
-4,916
| -7% | -$482K | 0.13% | 134 |
|
|
2025
Q3 | $7.12M | Buy |
+67,449
| New | +$6.99M | 0.18% | 95 |
|
|
2025
Q1 | $6.13M | Buy |
60,766
+8,931
| +17% | +$899K | 0.19% | 91 |
|
|
2024
Q4 | $4.63M | Buy |
51,835
+5,323
| +11% | +$469K | 0.15% | 109 |
|
|
2024
Q3 | $3.9M | Buy |
46,512
+3,686
| +9% | +$291K | 0.14% | 122 |
|
|
2024
Q2 | $3.3M | Buy |
42,826
+16,348
| +62% | +$1.2M | 0.13% | 127 |
|
|
2024
Q1 | $1.81M | Sell |
26,478
-34
| -0.1% | -$2.19K | 0.1% | 149 |
|
|
2023
Q4 | $1.53M | Buy |
26,512
+1,417
| +6% | +$75.6K | 0.1% | 170 |
|
|
2023
Q3 | $1.32M | Sell |
25,095
-543
| -2% | -$28.5K | 0.1% | 162 |
|
|
2023
Q2 | $1.39M | Buy |
25,638
+1,830
| +8% | +$95.6K | 0.1% | 160 |
|
|
2023
Q1 | $1.19M | Buy |
23,808
+3,337
| +16% | +$157K | 0.09% | 169 |
|
|
2022
Q4 | $947K | Buy |
20,471
+2,538
| +14% | +$110K | 0.09% | 182 |
|
|
2022
Q3 | $695K | Buy |
17,933
+1,490
| +9% | +$59.8K | 0.07% | 212 |
|
|
2022
Q2 | $613K | Buy |
16,443
+1,869
| +13% | +$76.1K | 0.06% | 234 |
|
|
2022
Q1 | $645K | Buy |
14,574
+4,313
| +42% | +$187K | 0.06% | 242 |
|
|
2021
Q4 | $436K | Buy |
10,261
+1,206
| +13% | +$50.7K | 0.04% | 323 |
|
|
2021
Q3 | $393K | Buy |
9,055
+144
| +2% | +$6.37K | 0.04% | 314 |
|
|
2021
Q2 | $381K | Sell |
8,911
-2,271
| -20% | -$95.5K | 0.03% | 305 |
|
|
2021
Q1 | $432K | Buy |
11,182
+3,649
| +48% | +$138K | 0.05% | 263 |
|
|
2020
Q4 | $271K | Sell |
7,533
-3,690
| -33% | -$133K | 0.03% | 354 |
|
|
2020
Q3 | $429K | Buy |
11,223
+1,051
| +10% | +$40.5K | 0.06% | 233 |
|
|
2020
Q2 | $357K | Buy |
10,172
+1,821
| +22% | +$65.6K | 0.05% | 252 |
|
|
2020
Q1 | $272K | Sell |
8,351
-2,291
| -22% | -$89.5K | 0.05% | 253 |
|
|
2019
Q4 | $481K | Buy |
10,642
+315
| +3% | +$13.2K | 0.09% | 173 |
|
|
2019
Q3 | $420K | Sell |
10,327
-84
| -0.8% | -$3.56K | 0.08% | 179 |
|
|
2019
Q2 | $447K | Sell |
10,411
-2,419
| -19% | -$93K | 0.09% | 173 |
|
|
2019
Q1 | $492K | Buy |
12,830
+634
| +5% | +$24.2K | 0.1% | 176 |
|
|
2018
Q4 | $431K | Buy |
12,196
+981
| +9% | +$35.6K | 0.1% | 178 |
|
|
2018
Q3 | $432K | Buy |
11,215
+92
| +0.8% | +$3.21K | 0.09% | 192 |
|
|
2018
Q2 | $364K | Buy |
+11,123
| New | +$335K | 0.08% | 236 |
|
|
2017
Q1 | – | Sell |
-12,979
| Closed | -$281K | – | 357 |
|
|
2016
Q4 | $281K | Sell |
12,979
-631
| -5% | -$13.8K | 0.07% | 240 |
|
|
2016
Q3 | $324K | Buy |
+13,610
| New | +$325K | 0.07% | 240 |
|
Other funds holding BSX
Caprock Group's BSX Position: Q2 2026 in Review
Caprock Group reduced its Boston Scientific (BSX) stake by 1.4% in Q2 2026, selling an estimated $34.5K and leaving 45,285 shares worth $1.93M. The position accounts for 0.04% of the portfolio, ranked #412.
Caprock Group first reported a position in BSX in Q3 2016 and has held it in 34 quarters since. The position peaked at $7.12M in Q3 2025. 1,470 funds tracked by Wall St. Rank hold BSX as of Q2 2026.
- Caprock Group held 45,285 shares of Boston Scientific worth $1.93M as of Q2 2026.
- Caprock Group sold 636 Boston Scientific shares in Q2 2026, an estimated $34.5K.
- Boston Scientific made up 0.04% of Caprock Group's portfolio in Q2 2026, its #412 holding.
- Caprock Group first reported a position in Boston Scientific in Q3 2016 and has held it in 34 quarters since.
- Caprock Group's Boston Scientific position peaked at $7.12M in Q3 2025.
- 1,470 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.
Based on Caprock Group's 13F filing for Q2 2026, filed 27 Jul 2026.